An open-label naturalistic pilot study of acamprosate in youth with autistic disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 21, Issue 6, 2011, Pages 565-569

  Erickson, Craig A ^a   Early, Maureen ^a   Stigler, Kimberly A ^a   Wink, Logan K ^a   Mullett, Jennifer E ^a   McDougle, Christopher J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ARIPIPRAZOLE; ATOMOXETINE; CLONIDINE; DESMOPRESSIN; GUANFACINE; LEVOTHYROXINE SODIUM; RISPERIDONE; SERTRALINE;

ARTICLE; AUTISM; CHILD; CLINICAL ARTICLE; DECREASED APPETITE; DRUG DOSE TITRATION; HUMAN; NAUSEA; PRESCHOOL CHILD; SCHOOL CHILD; SOCIAL DISABILITY; TREATMENT OUTCOME;

AUTISTIC DISORDER; CHILD; EXCITATORY AMINO ACID ANTAGONISTS; GABA ANTAGONISTS; HUMANS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; SOCIAL BEHAVIOR DISORDERS; TAURINE;

EID: 84555196270     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2011.0034     Document Type: Article

References (37)

1. Aldred S, Moore KM, Fitzgerald M, Waring RH: Plasma amino acid levels in children with autism and their families. J Autism Dev Disord 1:93-97, 2003. (Pubitemid 36323144)
2. Aman MG, Singh NN, Stewart AW, Field CJ: The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89:485-491, 1985. (Pubitemid 15104762)
3. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
4. Bear MF, Huber KM, Warren ST: The mGluR theory of fragile X mental retardation. Trends Neurosci 7:370-377, 2004. (Pubitemid 38829251)
5. Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW: Lamo-trigine therapy for autistic disorder: A randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2:175-181, 2001. (Pubitemid 37490163)
6. Blednov YA, Adron Harris R: Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: Relationship to acamprosate actions. Int J Neuropsychopharmacol 6:775-793, 2008.
7. Campbell M, Adams P, Small AM, Curren EL, Overall JE, Anderson LT, Lynch N, Perry R: Efficacy and safety of fenfluramine in autistic children. J Am Acad Child Adolesc Psychiatry 4:434-439, 1988.
8. Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M: Naltrexone in autistic children: Behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 6:1283-1291, 1993. (Pubitemid 23319191)
9. Chez MG, Buchanan TM, Becker M, Kessler J, Aimonovitch MC, Mrazek SR: Donepezil hydrochloride: A double-blind study in autistic children. J Pediatr Neurol 2:83-88, 2003.
10. Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL, Metzger LM, Shoushtari CS, Splinter R, Reich W: Validation of a brief quantitative measure of autistic traits: Comparison of the social responsiveness scale with the autism diagnostic interview-revised. J Autism Dev Disord 4:427-433, 2003. (Pubitemid 37127938)
11. Delahanty RJ, Kang JQ, Brune CW, Kistner EO, Courchesne E, Cox NJ, Cook EH, Jr., Macdonald RL, Sutcliffe JS: Maternal transmission of a rare GABRB3 signal peptide variant is associated with autism. Mol Psychiatry 2011.
12. DeLorey TM: GABRB3 gene deficient mice: A potential model of autism spectrum disorder. Int Rev Neurobiol 71:359-382, 2005.
13. Erickson CA, Mullett JE, McDougle CJ: Brief report: Acamprosate in Fragile X syndrome. J Autism Dev Disord 11:1412-1416, 2010.
14. Erickson CA, Posey DJ, Stigler KA, McDougle CJ. Glutamatergic function in autism. In: Glutamate in Neuropsychiatric Disorders. Edited by U. Heresco-Levy. Trivandrum, Kerala, India: Research Signpost; 2008; pp. 197-212.
15. Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ: A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psycho-pharmacology (Berl) 1:141-147, 2007. (Pubitemid 46294942)
16. Fatemi SH, Halt AR, Stary JM, Kanodia R, Schulz SC, Realmuto GR: Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry 8:805-810, 2002.
17. Fatemi SH, Reutiman TJ, Folsom TD, Thuras PD: GABA(A) receptor downregulation in brains of subjects with autism. J Autism Dev Disord 2:223-230, 2009.
18. Gupta T, Syed YM, Revis AA, Miller SA, Martinez M, Cohn KA, Demeyer MR, Patel KY, Brzezinska WJ, Rhodes JS: Acute effects of acamprosate and MPEP on ethanol Drinking-in-the-Dark in male C57BL/6J mice. Alcohol Clin Exp Res 11:1992-1998, 2008.
19. Guy W. ECDEU Assessment Manual for Psychopharmacology, Publication No. 76-338. Washington, DC: U.S. DHEW, NIMH; 1976.
20. Harris BR, Prendergast MA, Gibson DA, Rogers DT, Blanchard JA, Holley RC, Fu MC, Hart SR, Pedigo NW, Littleton JM: Acam-prosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 12:1779-1793, 2002. (Pubitemid 36008614)
21. Hogart A, Nagarajan RP, Patzel KA, Yasui DH, Lasalle JM: 15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders. Hum Mol Genet 6:691-703, 2007. (Pubitemid 46585668)
22. Kanner L: Autistic disturbances of affective contact. Nerv Child 2:217-250, 1943.
23. Kim SA, Kim JH, Park M, Cho IH, Yoo HJ: Association of GABRB3 polymorphisms with autism spectrum disorders in Korean trios. Neuropsychobiology 3:160-165, 2006.
24. Kotlinska J, Bochenski M: The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats. Eur J Pharmacol 598:57-63, 2008.
25. Mann K, Kiefer F, Spanagel R, Littleton J:Acamprosate: Recentfindings and future research directions. Alcohol Clin Exp Res 7:1105-1110, 2008.
26. Mason BJ, Heyser CJ: Acamprosate: A prototypic neuromodulator in the treatment of alcohol dependence. CNS Neurol Disord Drug Targets 1:23-32, 2010.
27. Mayer S, Harris B, Gibson DA, Blanchard J, Prendergast MA, Holley RC, Littleton J: Acamprosate has no effect on NMDA-induced toxicity but reduces toxicity induced by spermidine or by changing the medium in organotypic hippocampal slice cultures from rat. Alcohol Clin Exp Res 5:655-662, 2002. (Pubitemid 34522672)
28. Menold MM, Shao Y, Wolpert CM, Donnelly SL, Raiford KL, Martin ER, Ravan SA, Abramson RK, Wright HH, Delong GR, Cuccaro ML, Pericak-Vance MA, Gilbert JR: Association analysis of chromosome 15 gabaa receptor subunit genes in autistic disorder. J Neurogenet 15:245-259, 2001. (Pubitemid 34467884)
29. Naassila M, Hammoumi S, Legrand E, Durbin P, Daoust M: Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 4:802-809, 1998. (Pubitemid 28292462)
30. Page LA, Daly E, Schmitz N, Simmons A, Toal F, Deeley Q, Ambery F, McAlonan GM, Murphy KC, Murphy DG: In vivo 1H-magnetic resonance spectroscopy study of amygdala-hippocampal and parietal regions in autism. Am J Psychiatry 12:2189-2192, 2006. (Pubitemid 46114244)
31. Pierrefiche O, Daoust M, Naassila M: Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network. Neuro-pharmacology 1:35-45, 2004. (Pubitemid 38686309)
32. Posey D, Stigler K, Erickson CA, Azzouz F, Mullett J, Diener JT, McDougle CJ. A double-blind, placebo-controlled study of D-Cycloserine in children with autistic disorder. Paper presented at the 2008 Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Chicago, Illinois, 2008.
33. Posey DJ, Erickson CA, McDougle CJ: Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am 4:787-801, 2008.
34. Posey DJ, McDougle CJ: The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry 2:45-63, 2000. (Pubitemid 30421511)
35. Purcell AE, Jeon OH, Zimmerman AW, Blue ME, Pevsner J: Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology 9:1618-1628, 2001. (Pubitemid 33055480)
36. Shinohe A, Hashimoto K, Nakamura K, Tsujii M, Iwata Y, Tsuchiya KJ, Sekine Y, Suda S, Suzuki K, Sugihara G, Matsuzaki H, Minabe Y, Sugiyama T, Kawai M, Iyo M, Takei N, Mori N: Increased serum levels of glutamate in adult patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 8:1472-1477, 2006. (Pubitemid 44634960)
37. Sturmey P: Secretin is an ineffective treatment for pervasive developmental disabilities: A review of 15 double-blind randomized controlled trials. Res Dev Disabil 1:87-97, 2005. (Pubitemid 39601466)